Pasar al contenido principal

PAPEL DE LA INTERLEUCINA-38 EN LESIONES Y ENFERMEDADES DEL SISTEMA NERVIOSO CENTRAL

PID2020-120267RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lack of effects of Resolvin D1 after spinal cord injury in mice

  • Francos-Quijorna, Isaac
  • López-González, Néstor
  • Caro-Canton, Marc
  • Sánchez-Fernández, Alba
  • Hernández-Mir, Gerard
  • López-Vales, Rubén
Inflammation is a fundamental component of the body's response to injury or infection and is responsible for restoring tissue homeostasis and starting the wound healing process. To avoid excessive tissue damage, it is important to efficiently resolve inflammation once it is no longer necessary. In recent years, the discovery of pro-resolving lipid mediators derived from polyunsaturated fatty acids, such as Resolvin D1 (RvD1), has shed light on the resolution of inflammation. However, the impact of RvD1 on Spinal Cord Injury (SCI) remains unexplored. In this study, we provide direct evidence that the administration of RvD1 for one week after SCI fails to enhance resolution of inflammation and does not improve functional and histological outcomes. Our transcriptomic analysis reveals that RvD1 does not modulate inflammatory response pathways in the injured spinal cord but leads to significant changes in the expression of genes related to ribosomal function and extracellular matrix pathways. Unlike SCI, RvD1 treatment ameliorated neurological deficits in experimental autoimmune encephalomyelitis. Our findings represent the first report demonstrating that RvD1 treatment does not exert therapeutic actions in the context of SCI and suggest that this pro-resolving agonist may exert therapeutic actions in certain but not in all conditions involving an inflammatory component., This work was supported by Ministerio de Ciencia, Innovación y Universidades, la Agencia y del Fondo Europeo de Desarrollo Regional (proyecto PID2020-120267RB and PID2023-152474OB-I00 funded by MCIU/AEI/10.13039/501100011033/FEDER, UE) as well as by RICORS-Terav (RD24/0014/0001) funded by Instituto de Salud Carlos III and co-funded by European Union. MC-C and NL-G are recipient of the FPU fellowship from Ministerio de Ciencia, Innovación y Universidades and the Joan Oró-FI fellowship from Generalitat de Catalunya, respectively. R.L.-V. is the recipient of an ICREA Academia award., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Administration of Maresin-1 ameliorates the physiopathology of experimental autoimmune encephalomyelitis

  • Sánchez Fernández, Alba
  • Zandee, Stephanie|||0000-0003-0812-676X
  • Mastrogiovanni, Mauricio|||0000-0002-7119-1970
  • Charabati, Marc|||0000-0002-4595-1040
  • Rubbo, Homero|||0000-0002-7897-6551
  • Prat, Alexandre|||0000-0001-6188-0580
  • López Vales, Rubén|||0000-0001-7615-9550
Resolution of inflammation is an active and regulated process that leads to the clearance of cell debris and immune cells from the challenged tissue, facilitating the recovery of homeostasis. This physiological response is coordinated by endogenous bioactive lipids known as specialized pro-resolving mediators (SPMs). When resolution fails, inflammation becomes uncontrolled leading chronic inflammation and tissue damage, as occurs in multiple sclerosis (MS). SPMs and the key biosynthetic enzymes involved in SPM production were analysed by metabololipidomics and qPCR in active brain lesions, serum and peripheral blood mononuclear cells (PBMC) of MS patients as well as in the spinal cord of mice with experimental autoimmune encephalomyelitis (EAE). We also tested the therapeutic actions of the SPM coined Maresin-1 (MaR1) in EAE mice and studied its impact on inflammation by doing luminex and flow cytometry analysis. We show that levels of MaR1 and other SPMs were below the limit of detection or not increased in the spinal cord of EAE mice, whereas the production of pro-inflammatory eicosanoids was induced during disease progression. Similarly, we reveal that SPMs were undetected in serum and active brain lesion samples of MS patients, which was linked to impaired expression of the enzymes involved in the biosynthetic pathways of SPMs. We demonstrate that exogenous administration of MaR1 in EAE mice suppressed the protein levels of various pro-inflammatory cytokines and reduced immune cells counts in the spinal cord and blood. MaR1 also decreased the numbers of Th1 cells but increased the accumulation of regulatory T cells and drove macrophage polarization towards an anti-inflammatory phenotype. Importantly, we provide clear evidence that administration of MaR1 in mice with clinical signs of EAE enhanced neurological outcomes and protected from demyelination. This study reveals that there is an imbalance in the production of SPMs in MS patients and in EAE mice, and that increasing the bioavailability of SPMs, such as MaR1, minimizes inflammation and mediates therapeutic actions. Thus, these data suggest that immunoresolvent therapies, such as MaR1, could be a novel avenue for the treatment of MS. The online version contains supplementary material available at 10.1186/s12974-022-02386-1.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

HPLC-MS/MS Oxylipin Analysis of Plasma from Amyotrophic Lateral Sclerosis Patients

  • Mastrogiovanni, Mauricio|||0000-0002-7119-1970
  • Trostchansky, Andrés|||0000-0002-9721-7577
  • Naya, Hugo
  • Dominguez, Raúl
  • Marco, Carla
  • Povedano, Mònica
  • López Vales, Rubén|||0000-0001-7615-9550
  • Rubbo, Homero|||0000-0002-7897-6551
Oxylipins play a critical role in regulating the onset and resolution phase of inflammation. Despite inflammation is a pathological hallmark in amyotrophic lateral sclerosis (ALS), the plasma oxylipin profile of ALS patients has not been assessed yet. Herein, we develop an oxylipin profile-targeted analysis of plasma from 74 ALS patients and controls. We found a significant decrease in linoleic acid-derived oxylipins in ALS patients, including 9-hydroxy-octadecadienoic acid (9-HODE) and 13-HODE. These derivatives have been reported as important regulators of inflammation on different cell systems. In addition, some 5-lipoxygenase metabolites, such as 5-hydroxy- eicosatetraenoic acid also showed a significant decrease in ALS plasma samples. Isoprostanes of the F2α family were detected only in ALS patients but not in control samples, while the hydroxylated metabolite 11-HETE significantly decreased. Despite our effort to analyze specialized pro-resolving mediators, they were not detected in plasma samples. However, we found the levels of 14-hydroxy-docosahexaenoic acid, a marker pathway of the Maresin biosynthesis, were also reduced in ALS patients, suggesting a defective activation in the resolution programs of inflammation in ALS. We further analyze oxylipin concentration levels in plasma from ALS patients to detect correlations between these metabolites and some clinical parameters. Interestingly, we found that plasmatic levels of 13-HODE and 9-HODE positively correlate with disease duration, expressed as days since onset. In summary, we developed a method to analyze "(oxy)lipidomics" in ALS human plasma and found new profiles of metabolites and novel lipid derivatives with unknown biological activities as potential footprints of disease onset.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

CD200R1 Contributes to Successful Functional Reinnervation after a Sciatic Nerve Injury

  • Pannunzio, Bruno
  • Amo Aparicio, Jesús|||0000-0002-1294-6819
  • Julián, Camila
  • López Vales, Rubén|||0000-0001-7615-9550
  • Peluffo, Hugo|||0000-0001-6111-8668
  • Lago, Natalia|||0000-0002-5631-8558
Activating and inhibitory immune receptors play a critical role in regulating systemic and central nervous system (CNS) immune and inflammatory processes. The CD200R1 immunoreceptor induces a restraining signal modulating inflammation and phagocytosis in the CNS under different inflammatory conditions. However, it remains unknown whether CD200R1 has a role in modulating the inflammatory response after a peripheral nerve injury, an essential component of the successful regeneration. Expression of CD200R1 and its ligand CD200 was analyzed during homeostasis and after a sciatic nerve crush injury in C57Bl/6 mice. The role of CD200R1 in Wallerian Degeneration (WD) and nerve regeneration was studied using a specific antibody against CD200R1 injected into the nerve at the time of injury. We found an upregulation of CD200R1 mRNA after injury whereas CD200 was downregulated acutely after nerve injury. Blockade of CD200R1 significantly reduced the acute entrance of both neutrophils and monocytes from blood after nerve injury. When long term regeneration and functional recovery were evaluated, we found that blockade of CD200R1 had a significant effect impairing the spontaneous functional recovery. Taken together, these results show that CD200R1 has a role in mounting a successful acute inflammatory reaction after injury, and contributes to an effective functional recovery.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Novel antagonist of the type 2 lysophosphatidic acid receptor (LPA), UCM-14216, ameliorates spinal cord injury in mice

  • Khiar-Fernández, Nora
  • Zian, Debora
  • Vázquez-Villa, Henar|||0000-0001-7911-3160
  • Martínez, R. Fernando|||0000-0002-3278-6074
  • Escobar-Peña, Andrea
  • Foronda-Sainz, Román
  • Ray, Manisha
  • Puigdomenech Poch, Maria
  • Cincilla, Giovanni|||0000-0002-5242-0707
  • Sánchez-Martínez, Melchor|||0000-0002-3674-8577
  • Kihara, Yasuyuki
  • Chun, Jerold
  • López Vales, Rubén|||0000-0001-7615-9550
  • López-Rodríguez, María L.|||0000-0001-8607-1085
  • Ortega-Gutiérrez, Silvia|||0000-0002-0257-6754
Spinal cord injuries (SCIs) irreversibly disrupt spinal connectivity, leading to permanent neurological disabilities. Current medical treatments for reducing the secondary damage that follows the initial injury are limited to surgical decompression and anti-inflammatory drugs, so there is a pressing need for new therapeutic strategies. Inhibition of the type 2 lysophosphatidic acid receptor (LPA) has recently emerged as a new potential pharmacological approach to decrease SCI-associated damage. Toward validating this receptor as a target in SCI, we have developed a new series of LPA antagonists, among which compound 54 (UCM-14216) stands out as a potent and selective LPA receptor antagonist (E = 90%, IC = 1.9 μM, K = 1.3 nM; inactive at LPA receptors). This compound shows efficacy in an in vivo mouse model of SCI in an LPA-dependent manner, confirming the potential of LPA inhibition for providing a new alternative for treating SCI.